PneumoniaNDCNCT06526884
Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
A study testing Next Day Clinic in people with Pneumonia and Syncope, run by University of California, Los Angeles at 1 site in United States.
Trial summary
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pneumonia, Syncope, Congestive Heart Failure
- What is being tested?
- Next Day Clinic
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 570 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Jul 2024to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older
- About to be admitted through the ED for one of the NDC diagnoses or a synonym (per Study Protocol document), defined by the presence of a Plan to Admit order or Bed Request order, OR recently admitted under observation or inpatient status for one of the NDC diagnoses.
- Identified as at-risk for an avoidable hospitalization in the ED based on a pre-determined set of lab and vital parameters.
- Insurance that authorizes the patient to follow-up at UCLA Health, or self-pay
- Admitted or being admitted to an internal medicine service
Who cannot join
- Heart or lung transplant recipient with concern for graft dysfunction
- Pregnant
- Enrolled in hospice
- Admitted to a critical care service
- ED deems discharge unsafe due to complex social or medical factors
- Active malignant cancer (per Council of State and Territorial Epidemiologists value set)
Show all 14Show fewer
- Pulmonary arterial hypertension (per Joint Commission value set)
- Undergoing workup for solid organ transplant
- Interstitial lung disease (including pulmonary fibrosis) (per Higher Level 7 value set)
- Requiring inpatient procedure or surgery defined by the presence of an anesthesia event or operating room encounter.
- The ED deems discharge unsafe due to complex social or medical factors.
- Transferred to an ineligible hospital
- Note:
- The Health System plans to limit the volume of referrals to the NDC by only referring patients who have an even birth date (this is more equitable than first-come-first-serve, because wage workers are more likely to come to the ED later in the day; even/odd birth date theoretically keeps more spots open for patients presenting to the ED later).
Trial locations and contacts
1 site in 1 country.
United States1 site
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90024
About this study
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions [UVAS] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Read the detailed description
NDC is a hospital avoidance model with the potential to simultaneously improve the quality and safety of acute care, reduce costs, and address hospital/ED overcrowding. This novel hospital avoidance program will divert patients from the ED who have been diagnosed with the following conditions and meet certain clinical criteria:
- Diabetic Foot Infection/Osteomyelitis
- Cellulitis
- Congestive Heart Failure
- Syncope
- Pyelonephritis/Urinary Tract Infection
- Pneumonia
- Acute Kidney Infection
- Conditions
- Pneumonia, Syncope, Congestive Heart Failure, Cellulitis, Pyelonephritis, AKI - Acute Kidney Injury
- Being tested
- Next Day Clinic
- Keywords
- Patient safety, Cost effectiveness, Avoidable hospitalizations
- Medical subject headings
- Pneumonia, Syncope, Heart Failure, Cellulitis, Pyelonephritis, Acute Kidney Injury, Osteomyelitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Next Day ClinicOther
A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
| Study group | Role | What they receive |
|---|---|---|
| ED-initiated hospitalization | No intervention | Patients with odd birthdays will be routed to standard-of-care ED-initiated hospitalization pathways. |
| Next Day Clinic | Experimental | Patients with even birthdays who meet inclusion criteria will be given the option to receive care in the Next Day Clinic to avoid hospitalization. Receives: Other: Next Day Clinic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Days alive and out of hospital (DAOH)
Cumulative number of days alive and not admitted or boarding in a hospital or emergency department
Measured: 30 days from index ED visit
Secondary outcomes (6)
Global health-related quality of life
Composite PROMIS-29+2 score (patient reported outcome measurement information system). PROMIS stands for Patient-Reported Outcomes Measurement Information System. High scores mean more of the concept being measured.
Measured: 30 days from index ED visit
Patient experience
Measured by PSQ-18 (patient satisfaction questionnaire). PSQ stands for Patient Satisfaction Questionnaire. High scores indicate higher levels of satisfaction.
Measured: 30 days from index ED visit
Financial analysis
Total cost per day of treatment
Measured: Through study completion, an average of 12 months
Cost effectiveness analysis
Total cost per day alive and out of hospital
Measured: Through study completion, an average of 12 months
Hospitalizations avoided
Each NDC referral with a preceding Plan to Admit order or Bed Request order (regardless of treatment arm) will be considered an avoided hospitalization, given that the presence of one of these orders establishes that the counterfactual for NDC treatment in hospitalization.
Measured: Through study completion, an average of 12 months
Hospital bed-days saved
For each referral to the NDC, the number of hospital bed-days saved will be established by using the mean length of stay for patients treated per-protocol in the control condition matched for the same presenting illness.
Measured: Through study completion, an average of 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jul 2024
- Study start22 Jul 2024
- Primary completion20 Jan 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized encouragement trial
- Masking
- None (open label)
- Enrolment
- 570 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Richard K. Leuchter, MD, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06526884
- Sponsor's protocol ID
- 24-000913
- Acronym
- NDC
- Status last verified
- May 2026
- First submitted
- 17 Jul 2024
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified data may be uploaded to a data repository system such as Vivli.
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)
- ClinicalTrials.gov ID
- NCT06526884
- Acronym / sponsor ID
- NDC / 24-000913
- Conditions
- Pneumonia, Syncope, Congestive Heart Failure, Cellulitis, Pyelonephritis, AKI - Acute Kidney Injury
- Keywords
- Patient safety, Cost effectiveness, Avoidable hospitalizations
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 570 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- 22 Jul 2024 (actual)
- Primary completion
- 20 Jan 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 30 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions [UVAS] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Detailed description
NDC is a hospital avoidance model with the potential to simultaneously improve the quality and safety of acute care, reduce costs, and address hospital/ED overcrowding. This novel hospital avoidance program will divert patients from the ED who have been diagnosed with the following conditions and meet certain clinical criteria:
- Diabetic Foot Infection/Osteomyelitis
- Cellulitis
- Congestive Heart Failure
- Syncope
- Pyelonephritis/Urinary Tract Infection
- Pneumonia
- Acute Kidney Infection
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomized encouragement trial
| Arm | Type | Receives |
|---|---|---|
| ED-initiated hospitalization | No intervention | –Patients with odd birthdays will be routed to standard-of-care ED-initiated hospitalization pathways. |
| Next Day Clinic | Experimental | Other: Next Day ClinicPatients with even birthdays who meet inclusion criteria will be given the option to receive care in the Next Day Clinic to avoid hospitalization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 18 years of age or older
- About to be admitted through the ED for one of the NDC diagnoses or a synonym (per Study Protocol document), defined by the presence of a Plan to Admit order or Bed Request order, OR recently admitted under observation or inpatient status for one of the NDC diagnoses.
- Identified as at-risk for an avoidable hospitalization in the ED based on a pre-determined set of lab and vital parameters.
- Insurance that authorizes the patient to follow-up at UCLA Health, or self-pay
- Admitted or being admitted to an internal medicine service
Key exclusion criteria (14 listed)
- Heart or lung transplant recipient with concern for graft dysfunction
- Pregnant
- Enrolled in hospice
- Admitted to a critical care service
- ED deems discharge unsafe due to complex social or medical factors
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Next Day ClinicA dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative. | Other | Next Day Clinic |
Primary outcome
Days alive and out of hospital (DAOH)
Time frame: 30 days from index ED visit
Cumulative number of days alive and not admitted or boarding in a hospital or emergency department
6 secondary outcomes
Global health-related quality of life
Time frame: 30 days from index ED visit
Patient experience
Time frame: 30 days from index ED visit
Financial analysis
Time frame: Through study completion, an average of 12 months
Cost effectiveness analysis
Time frame: Through study completion, an average of 12 months
Hospitalizations avoided
Time frame: Through study completion, an average of 12 months
Hospital bed-days saved
Time frame: Through study completion, an average of 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Individual participant dataSharing planned: No. De-identified data may be uploaded to a data repository system such as Vivli.
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Next Day Clinic in people with Pneumonia and Syncope, run by University of California, Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Days alive and out of hospital (DAOH) (time frame: 30 days from index ED visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.